171 related articles for article (PubMed ID: 35081854)
1. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
[TBL] [Abstract][Full Text] [Related]
3. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
5. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
[TBL] [Abstract][Full Text] [Related]
6. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
[TBL] [Abstract][Full Text] [Related]
7. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
8. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
9. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
[No Abstract] [Full Text] [Related]
10. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
[TBL] [Abstract][Full Text] [Related]
11. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions.
Farberg AS; Glazer AM; White R; Rigel DS
J Drugs Dermatol; 2017 May; 16(5):428-431. PubMed ID: 28628677
[TBL] [Abstract][Full Text] [Related]
12. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
[No Abstract] [Full Text] [Related]
13. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations.
Hyams DM; Covington KR; Johnson CE; Plasseraud KM; Cook RW
Future Oncol; 2021 Feb; 17(5):517-527. PubMed ID: 33021104
[No Abstract] [Full Text] [Related]
14. CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.
Berry DE; Schefler AC; Seider MI; Materin M; Stinnett S; Mruthyunjaya P;
Retina; 2020 Feb; 40(2):214-224. PubMed ID: 31972790
[TBL] [Abstract][Full Text] [Related]
15. Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma.
Dubin DP; Dinehart SM; Farberg AS
Am J Clin Dermatol; 2019 Dec; 20(6):763-770. PubMed ID: 31359351
[TBL] [Abstract][Full Text] [Related]
16. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
[TBL] [Abstract][Full Text] [Related]
17. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
18. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
[TBL] [Abstract][Full Text] [Related]
19. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
[TBL] [Abstract][Full Text] [Related]
20. Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma.
Nguyen BT; Kim RS; Bretana ME; Kegley E; Schefler AC
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):421-427. PubMed ID: 29185101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]